ArticleNature2021
An engineered IL-2 partial agonist promotes CD8
Abstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions.Science China. Life sciences · 2026Pooled it
- In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy.Cancer immunology research · 2026Article
- Lactate as a Master Regulator of Immune Suppression: From Metabolic Waste to Epigenetic Checkpoint in Colorectal Cancer.International journal of molecular sciences · 2026Review
- CD25 genetic ablation on lymphoid cell lines to obtain models of stimulation through the Interleukin-2 beta/gamma receptor.Scientific reports · 2026Article
- Spatiotemporal dynamics of adoptively transferred stem-like CD8bioRxiv : the preprint server for biology · 2026Article
- Advances in IL-2 Family Cytokine-Based Cancer Therapies: Overcoming Challenges Through Molecular Engineering and Delivery Strategies.Immune network · 2026Review
- Regulators of CD8Nature reviews. Immunology · 2026Review
- Epigenetic regulation of T cell exhaustion in cancer.Nature reviews. Cancer · 2026Review
- Distribution and function of human long-lasting T cells in aging and non-small cell lung cancer.Frontiers in immunology · 2026Review
- Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy.Cellular & molecular immunology · 2026Review
- HERV-K TM Subunit Elicits CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives.Immuno-oncology technology · 2025Review
- The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee.Journal for immunotherapy of cancer · 2025Review
- Improving T cell expansion by optogenetically engineered bacteria-loaded MMP-2-responsive cyclophosphamide for antitumor immunotherapy.Journal of nanobiotechnology · 2025Article
- Intrinsic Properties of the Lymph Node Render It Immunologically Susceptible to Metastasis.Cancer discovery · 2025Article
- Article
- Cytokine-mediated regulation of immune cell metabolic pathways in the tumor microenvironment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis.Cancer cell · 2025Article
- Long-acting IL-2 release from pressure-fused biomineral tablets promotes antitumor immune response.Nature cancer · 2025Article
- DON-Loaded Nanodrug-T Cell Conjugates With PD-L1 Blockade for Solid Tumor Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Fei Mo *Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-8601-2568
Zhiya Yu *Surgery Branch, National Cancer Institute, Bethesda, MD, USA.
Peng Li *Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Jangsuk OhLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Rosanne SpolskiLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Liang ZhaoJohns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-2126-6778
Caleb R GlassmanDepartment of Molecular and Cellular Physiology and Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3342-7989
Tori N YamamotoSurgery Branch, National Cancer Institute, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-1965-7822
Yun ChenNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Filip M GolebiowskiNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-8011-2162
Dalton HermansLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Sonia Majri-MorrisonDepartment of Molecular and Cellular Physiology and Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Lora K PictonDepartment of Molecular and Cellular Physiology and Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Wei LiaoLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Min RenLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Xiaoxuan ZhuangLaboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Suman MitraLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Jian-Xin LinLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Luca GattinoniCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2239-3282
Jonathan D PowellJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Nicholas P RestifoSurgery Branch, National Cancer Institute, Bethesda, MD, USA. drnickrestifo@gmail.com.ORCID http://orcid.org/0000-0003-4229-4580
K Christopher GarciaDepartment of Molecular and Cellular Physiology and Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA. kcgarcia@stanford.edu.ORCID http://orcid.org/0000-0001-9273-0278
Warren J LeonardLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. leonardw@nhlbi.nih.gov.ORCID http://orcid.org/0000-0002-5740-7448
Funding
TR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI JONATHAN P SCHNECK · 2019 to 2026
$11.5MStructure-based engineering of immune cytokine signalingR01AI051321 · NIAID · STANFORD UNIVERSITY · PI Kenan Christopher GARCIA · 2002 to 2026
$5.6MStructure, function and engineering of immune cytokine receptor signalingR37AI051321 · NIAID · STANFORD UNIVERSITY · PI GARCIA, KENAN CHRISTOPHER · 2013 to 2022
$4.2MA central role for mTOR in Determining T Cell Activation versus ToleranceR01AI077610 · NIAID · JOHNS HOPKINS UNIVERSITY · PI POWELL, JONATHAN D · 2009 to 2019
$4.0MIntramural NIH HHS Z99 HL999999NIAID NIH HHS R01 AI051321NIAID NIH HHS R01 AI077610NIAID NIH HHS R37 AI051321NIBIB NIH HHS P41 EB028239
Abstract
Adoptive transfer of antigen-specific T cells represents a major advance in cancer immunotherapy, with robust clinical outcomes in some patients
Indexed as
Drug Partial AgonismAnimalsCD8-Positive T-LymphocytesCell DifferentiationInterleukin-2MelanomaMiceMitochondriaMutant ProteinsPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Antigen, T-CellSTAT5 Transcription FactorStem CellsT Cell Transcription Factor 1Translational Research, BiomedicalInterleukin-2Mutant ProteinsReceptors, Antigen, T-CellSTAT5 Transcription FactorT Cell Transcription Factor 1TCF7 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.